Procainamide

Also known as Procan®, Pronestyl®, p-Aminobenzoic diethylaminoethylamide, p-Amino-N-(2-diethylaminoethyl)benzamide, Biocoryl, Procainamida, Procainamidum

Procainamide (PCA) is a medication of the antiarrhythmic class used for the treatment of cardiac arrhythmias. It is a sodium channel blocker of cardiomyocytes; thus it is classified by the Vaughan Williams classification system as class Ia. In addition to blocking the INa current, it inhibits the IKr rectifier K+ current. Procainamide is also known to induce a voltage-dependent open channel block on the batrachotoxin (BTX)-activated sodium channels in cardiomyocytes.

In the Vinony graph

Vinony's link graph records 399 inbound references to Procainamide, and connects out to heart arrhythmia, antiarrhythmic agent and atropine.

It is catalogued under topics including 4-Aminophenyl compounds, Antiarrhythmic agents and Benzamides.

Vinony links it to 25 Wikipedia language editions.

Chemical data

Formula: C13H21N3O
Molecular weight: 235.33 g/mol
IUPAC name: 4-amino-N-[2-(diethylamino)ethyl]benzamide
SMILES: CCN(CC)CCNC(=O)C1=CC=C(C=C1)N
InChIKey: REQCZEXYDRLIBE-UHFFFAOYSA-N
XLogP: 0.9
Polar surface area: 58.4 Å²
H-bond donors: 2
H-bond acceptors: 3
Formal charge: 0

via PubChem

Drug data · ChEMBL

Max clinical phase: Approved
Molecule type: Small molecule
First approval: 1950
Admin. routes: oral, parenteral
Indications: atrial fibrillation, heart failure, cardiac arrhythmia, myocardial infarction

via ChEMBL · EBI